CSL Limited (CSL.AX)

275.80 +0.41 (+0.15%) 收市：04:10PM AEST

CSL Limited

655 Elizabeth Street
Melbourne, VIC 3000
Australia
61 3 9389 1911
https://www.csl.com.au

版塊: Healthcare
行業: Biotechnology
全職員工: 32,065

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Paul F. McKenzie Ph.D.	MD, CEO & Executive Director	4.21M	無	1966
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI	Chief Financial Officer	3.13M	無	1965
Mr. Mark Dehring	Head of Investor Relations	無	無	無
Mr. Gregory Boss B.S., BS(Hons), J.D.	Executive VP of Legal & General Counsel	1.68M	無	1961
Christina Hickie	Senior Manager of Communications	無	無	無
Ms. Roanne Parry	Chief Human Resources Officer	無	無	無
Dr. Karen Etchberger	Executive Vice President of Quality & Business Services	1.58M	無	1958
Ms. Jemimah Brennan	Head of Communications - Asia Pacific	無	無	無
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D.	Senior Vice President of Research	無	無	1962
Dr. William Mezzanotte M.D., M.P.H.	Executive VP & Head of Research and Development	2.23M	無	1959

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 AUD。

描述

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

公司管治

截至 2024年5月1日 止，CSL Limited 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：4；董事會：4；股東權利：1；現金賠償：4。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。